Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

被引：2

作者：

Papayannidis, Cristina ^{[1
]}

Smith, B. Douglas ^{[2
]}

Heuser, Michael ^{[3
]}

Montesinos, Pau ^{[4
,5
]}

Sekeres, Mikkael A. ^{[6
]}

Oriol, Albert ^{[7
]}

Schiller, Gary ^{[8
]}

Candoni, Anna ^{[9
]}

Jamieson, Catriona ^{[10
,11
]}

Hoang, Caroline J. ^{[12
]}

Ma, Weidong Wendy ^{[12
]}

Zeremski, Mirjana ^{[12
]}

O'Connell, Ashleigh ^{[12
]}

Chan, Geoffrey ^{[12
]}

Cortes, Jorge E. ^{[13
]}

机构：

[1] Univ Bologna, Bologna, Italy

[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Hannover Med Sch, Hannover, Germany

[4] Hosp Univ & Politecn La Fe, Valencia, Spain

[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain

[6] Cleveland Clin, Cleveland, OH 44106 USA

[7] Inst Catala Oncol, Badalona, Spain

[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[9] Azienda Sanit Univ Integrata Udine, Udine, Italy

[10] UCSD Moores Canc Ctr, La Jolla, CA USA

[11] Sanford Stem Cell Clin Ctr, La Jolla, CA USA

[12] Pfizer Inc, New York, NY USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

acute myeloid leukemia; glasdegib; low-dose cytarabine; overall survival; randomized clinical trial; AML;

D O I：

10.1016/j.clml.2019.07.111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-271

引用

页码：S228 / S229

页数：2